Abivax SA American Depositary Shares
Symbol: ABVX (NASDAQ)
87.66
▼ (-1.78%) -1.590
Company Description:
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Key Stats
- Today's Open: $90
- Today's High: $91.34
- Today's Low: $86.262
- Today's Volume: 715.32K
- Yesterday Close: $89.25
- Yesterday High: $91.3
- Yesterday Low: $87.525
- Yesterday Volume: 1.20M
- Last Min Volume: 20
- Last Min High: $87.66
- Last Min Low: $87.66
- Last Min VWAP: $87.66
Company Profile
- Name: Abivax SA American Depositary Shares
- Website: https://www.abivax.com
- Listed Date: 2023-10-20
- Location: ,
- Market Status: Active
- CIK Number: 0001956827
- SIC Code:
- SIC description:
- Market Cap: $6.80B
- Round Lot: 100
- Outstanding Shares: 75.57M
- Asset Type: ADRC
RECENT FILINGS FOR ABVX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-08 | 6-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-07-31 | SCHEDULE 13D/A | View |
| 2025-07-24 | 424B5 | View |
| 2025-07-24 | 6-K | View |
| 2025-07-24 | FWP | View |
| 2025-07-23 | FWP | View |
| 2025-07-23 | 424B5 | View |
| 2025-07-23 | F-3ASR | View |
| 2025-07-22 | 6-K | View |
| 2025-06-11 | 6-K | View |
| 2025-06-02 | 6-K | View |
| 2025-04-29 | 6-K | View |
| 2025-04-22 | 6-K | View |
| 2025-04-11 | SCHEDULE 13G | View |
| 2025-03-24 | S-8 | View |
| 2025-03-24 | 20-F | View |
| 2025-03-24 | 6-K | View |
| 2025-02-14 | SCHEDULE 13D/A | View |
| 2025-01-10 | 6-K | View |
Latest News on ABVX